Economy/Home · Economy

Hengrui Pharmaceuticals Receives Clinical Trial Approval for Bladder Cancer Combination Therapy... Track Record of Collaboration with HLB and Dong-A ST Draws Attention

China's Hengrui Pharmaceuticals has received clinical trial approval notices for a new anticancer drug combination therapy for bladder cancer treatment. Hengrui has a track record of technology transfer and new drug development partnerships with Korean pharmaceutical and biotech companies, including

Wooil Shim
Staff Reporter
7 min read
Hengrui Pharmaceuticals Receives Clinical Trial Approval for Bladder Cancer Combination Therapy... Track Record of Collaboration with HLB and Dong-A ST Draws Attention
CBC News

China's Hengrui Pharmaceuticals has received clinical trial approval notices for a new anticancer drug combination therapy for bladder cancer treatment. Hengrui has a track record of technology transfer and new drug development partnerships with Korean pharmaceutical and biotech companies, including HLB affiliates and Dong-A ST.

According to a disclosure filed with the Shanghai Stock Exchange on the 26th, Hengrui's subsidiaries Suzhou Sunrise Biopharmaceutical, Shanghai Sunrui Pharmaceutical, and Shanghai Hengrui Pharmaceutical received clinical trial approval notices from China's National Medical Products Administration for SHR-2005 injection, SHR-1501 for injection, and adebrelimab injection. The trial covers a bladder cancer treatment combining SHR-2005 and SHR-1501, with the optional addition of adebrelimab injection and BCG. After reviewing the clinical trial application submitted on May 7, the National Medical Products Administration judged that it met the requirements for drug registration. Hengrui plans to proceed with the trial in the near future.

Looking at each drug, SHR-2005 is an innovative anticancer drug independently developed by Hengrui and is being studied for bladder cancer treatment, with no drugs of the same class currently marketed in China or abroad. SHR-1501 is an interleukin-15 (IL-15) fusion protein independently developed by Hengrui that promotes the proliferation of T cells, B cells, and natural killer (NK) cells to exert antitumor effects. Abroad, Anktiva, a drug of the same class, has been approved for sale in the United States, but no drug targeting the same target has yet been approved in China. Adebrelimab is a humanized anti-PD-L1 monoclonal antibody that binds to PD-L1, blocks the PD-1/PD-L1 signaling pathway, and induces the immune system's antitumor activity. In China, it has been approved for first-line treatment of extensive-stage small cell lung cancer and for perioperative treatment of operable non-small cell lung cancer patients meeting certain conditions. This bladder cancer trial is a separate development process from the existing lung cancer indications.

Hengrui's track record of collaboration with Korean companies also draws attention. Eleva Therapeutics, HLB's U.S. subsidiary, signed a global license agreement with Hengrui in 2023 regarding the immuno-oncology drug camrelizumab. The agreement relates to the development and commercialization of a liver cancer treatment combining camrelizumab and rivoceranib, covering regions excluding Korea and Greater China. HLB Life Science received the rights to develop and commercialize the targeted anticancer drug pyrotinib in Korea from Hengrui in September 2020, and Dong-A ST received the Korean development and commercialization rights for the immuno-oncology candidate SHR-1701 in November 2020.

However, the drugs covered by the newly approved bladder cancer trial differ from those covered by the existing contracts with Korean companies, and the disclosure did not include any content regarding HLB's or Dong-A ST's participation in the trial.

In terms of R&D investment, approximately 56.6 million yuan has been invested in SHR-2005, approximately 129.5 million yuan in SHR-1501, and approximately 1.37 billion yuan in adebrelimab. Hengrui's bladder cancer combination therapy research and its existing contracts with Korean companies are separate business areas.

[This article is provided for informational purposes as an investment reference and does not recommend the purchase or sale of any specific stock. The information requires verification and may vary depending on market conditions. Investment decisions and any resulting responsibility rest with the investor. AI provided partial assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.